Summit Therapeutics (SMMT) Competitors $24.12 +0.50 (+2.12%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SMMT vs. TAK, ARGX, BNTX, ONC, TEVA, ITCI, GMAB, RDY, ASND, and MRNAShould you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Summit Therapeutics vs. Takeda Pharmaceutical argenx BioNTech Beigene Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Summit Therapeutics (NASDAQ:SMMT) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation. Which has more volatility & risk, SMMT or TAK? Summit Therapeutics has a beta of -0.46, indicating that its stock price is 146% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Does the MarketBeat Community favor SMMT or TAK? Summit Therapeutics received 210 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 58.57% of users gave Summit Therapeutics an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes31158.57% Underperform Votes22041.43% Takeda PharmaceuticalOutperform Votes10157.06% Underperform Votes7642.94% Do institutionals and insiders hold more shares of SMMT or TAK? 4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 88.3% of Summit Therapeutics shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is SMMT or TAK more profitable? Takeda Pharmaceutical has a net margin of 4.53% compared to Summit Therapeutics' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 9.39% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Takeda Pharmaceutical 4.53%9.39%4.53% Do analysts rate SMMT or TAK? Summit Therapeutics currently has a consensus price target of $37.50, suggesting a potential upside of 58.23%. Given Summit Therapeutics' higher possible upside, research analysts clearly believe Summit Therapeutics is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer SMMT or TAK? In the previous week, Summit Therapeutics had 17 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 25 mentions for Summit Therapeutics and 8 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.86 beat Summit Therapeutics' score of 0.70 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 11 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, SMMT or TAK? Takeda Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K24,975.74-$614.93M-$0.31-76.45Takeda Pharmaceutical$4.58T0.01$994.06M$0.4038.15 SummaryTakeda Pharmaceutical beats Summit Therapeutics on 10 of the 17 factors compared between the two stocks. Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SMMT vs. The Competition Export to ExcelMetricSummit TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.48B$6.84B$5.53B$7.73BDividend YieldN/A3.09%5.11%4.22%P/E Ratio-84.647.3722.4418.38Price / Sales24,975.74239.86390.71103.40Price / CashN/A65.8538.1834.62Price / Book215.456.456.704.22Net Income-$614.93M$142.94M$3.22B$248.14M7 Day Performance-28.77%2.47%2.23%2.49%1 Month Performance16.63%-1.04%-0.93%1.01%1 Year Performance503.05%1.91%17.52%4.98% Summit Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SMMTSummit Therapeutics2.6628 of 5 stars$24.12+2.1%$37.50+55.5%+508.8%$17.79B$700,000.00-86.14110Upcoming EarningsAnalyst ForecastGap DownTAKTakeda Pharmaceutical2.9069 of 5 stars$14.92+1.4%N/A+16.0%$47.47B$4.58T37.3047,300News CoverageARGXargenx2.5145 of 5 stars$598.62+0.4%$699.28+16.8%+67.7%$36.37B$2.19B-680.25650Positive NewsBNTXBioNTech2.379 of 5 stars$101.94+3.2%$143.44+40.7%+18.2%$24.46B$2.75B-48.543,080Upcoming EarningsONCBeigene2.341 of 5 stars$230.09-0.4%$316.71+37.6%N/A$22.75B$3.81B-27.929,000Analyst ForecastAnalyst RevisionGap UpTEVATeva Pharmaceutical Industries3.2593 of 5 stars$13.25-2.9%$23.43+76.8%+10.5%$15.02B$16.54B-9.1436,800Upcoming EarningsAnalyst RevisionPositive NewsITCIIntra-Cellular Therapies0.8805 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Upcoming EarningsAnalyst ForecastGMABGenmab A/S4.445 of 5 stars$20.11+0.3%$39.17+94.8%-27.2%$13.31B$21.53B11.561,660Analyst RevisionRDYDr. Reddy's Laboratories1.8477 of 5 stars$13.66-0.1%$17.00+24.5%-6.4%$11.40B$311.31B21.7524,800Upcoming EarningsASNDAscendis Pharma A/S2.3354 of 5 stars$160.33-2.9%$204.67+27.7%+18.9%$9.78B$363.64M-22.58640Upcoming EarningsPositive NewsMRNAModerna4.337 of 5 stars$25.17+1.8%$58.70+133.2%-75.1%$9.73B$3.20B-2.713,900Upcoming EarningsGap Down Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors argenx Competitors BioNTech Competitors Beigene Competitors Teva Pharmaceutical Industries Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Moderna Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SMMT) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SMMT Stock Free SMMT Stock Alerts